Posted by Michael Wonder on 31 Jan 2022
Trevena announces submission of new drug application in China for Olinvyk by its partner Jiangsu Nhwa Pharmaceutical
27 January 2022 - Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to intravenous morphine, conducted in China by Nhwa.
Trevena today announced that China’s National Medical Products Administration has accepted submission of a new drug application for oliceridine injection.
